If you have been reading about mass spectrometry and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-22. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
| Property | Value | Notes |
|---|---|---|
| Solid-state storage | -20 degrees Celsius or lower | Desiccated and protected from light |
| Solution stability | Short and method-dependent | Confirm by stability testing |
| Purity assessment | Reversed-phase HPLC | Reported as area percent |
| Identity confirmation | LC-MS or comparable method | Mass match against expected value |
| Common synonyms | MT-II; melanotan II | Informal and catalogue names |
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
A substrate (quartz, silicon, stainless steel, carbon fibers, etc.) is coated with a catalytic metal (Fe, Co, Ni) layer. Typically that layer is iron and is deposited via sputtering to a thickness of 1–5 nm. A 10–50 nm underlayer of alumina is often also put down on the substrate first. This imparts controllable wetting and good interfacial properties. When the substrate is heated to the growth temperature (~600 to 850 °C), the continuous iron film breaks up into small islands with each island then nucleating a carbon nanotube. The sputtered thickness controls the island size and this in turn determines the nanotube diameter. Thinner iron layers drive down the diameter of the islands and drive down the diameter of the nanotubes grown. The amount of time the metal island can sit at the growth temperature is limited as they are mobile and can merge into larger (but fewer) islands. Annealing at the growth temperature reduces the site density (number of CNT/mm2) while increasing the catalyst diameter. The as-prepared carbon nanotubes always have impurities such as other forms of carbon (amorphous carbon, fullerene, etc.) and non-carbonaceous impurities (metal used for catalyst). These impurities need to be removed to make use of the carbon nanotubes in applications.
Two people were killed by Russian shelling in Ukrainsk, Donetsk Oblast. One person was killed in a separate attack in Komar. Russia launched an air attack on Myrhorod Air Base in Poltava Oblast. The Ukrainian Air Force acknowledged damage, with two of the base's six Su-27s destroyed by an Iskander missile with a cluster warhead. A drone attack was reported in Sevastopol and other parts of Crimea, with the Ukrainian Air Force later claiming to have struck an ammunition dump using six Storm Shadow cruise missiles. The ammunition dump was also believed to host a "Shahed drone warehouse". Russian sources claimed that five aerial targets were shot down. Ukrainian drone attacks left parts of Belgorod Oblast without power. Ukrainian media reported that a drone strike the Oskol Electrometallurgical Plant, Russia's only full-cycle metallurgical enterprise, in Stary Oskol. Scouts from the Ukrainian Rubizh Brigade captured "several dozen Russian soldiers", mostly mobilised conscripts, in an unspecified location. Dutch defence minister Kajsa Ollongren announced that the export permits allowing the export of 24 F-16s to Ukraine had been granted, with their arrival set on a "confidential" date. The SBU claimed to have foiled a coup by a Russian-backed group against the Ukrainian government that was scheduled on 30 July. Russia claimed to have captured an ATACMS missile guidance system intact and was studying it to "identify any weak spots".
== Workflow == The Lanthanide group of elements are used for tagging antibodies, as the background in biological samples is very low. When choosing the appropriate isotope for the biomarker, low expression biomarkers should be paired with an isotope that has high signal intensity. If a less pure isotope must be used, it should be paired with a low expression biomarker, to minimize any non specific binding or background. Isotope polymers are constructed using diethylenetriaminepentaacetic acid (DTPA) chelator to bind ions together. The polymer terminates with a thiol or a maleimide that links it to reduced disulfides in the Fc region of the antibody. Four to five polymers are bound to an antibody, resulting in about 100 isotope atoms per antibody. Tagged antibodies may be in solution, conjugated to beads, or surface immobilized. The cell staining follows the same procedures as in fluorescent staining for flow cytometry. To distinguish between live and dead cells, cells can be probed with rhodium, an intercalator which can only penetrate dead cells. Then all cells are fixed and stained with iridium, which penetrates all cells, to be able to visualize which are alive. The cell introduction method of the mass cytometer is an aerosol splitter injection. The cells are then captured in a stream of argon gas, then transported to the plasma where they are vaporized, atomized, and ionized. The cell is now a cloud of ions, which passes into the ion optics center. Then a time of flight analyzer is used to measure the mass of the ions.
== Research == Osemozotan was under development for the treatment of anxiety disorders, generalized anxiety disorder, insomnia, irritable bowel syndrome, and major depressive disorder. It reached phase 2 clinical trials, but as of December 2025, development for all indications has been suspended, with suspension having occurred in May 2014. Besides the preceding indications, osemozotan has also been studied for potential treatment of pain, aggression, obsessive–compulsive disorder, and stimulant use disorder.
Setmelanotide, sold under the brand name Imcivree, is a medication used for the treatment of genetic obesity caused by a rare single-gene mutation. The most common side effects include injection site reactions, skin hyperpigmentation (skin patches that are darker than surrounding skin), headache and gastrointestinal side effects (such as nausea, diarrhea, and abdominal pain), among others. Spontaneous penile erections in males and adverse sexual reactions in females have occurred with treatment. Depression and suicidal ideation have also occurred with setmelanotide. Setmelanotide was approved for medical use in the United States in November 2020, and in the European Union in July 2021. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Sources: en.wikipedia.org
k¢ is the capacity factor of the complexed solute and the free solute k¢S is the capacity factor of the free solute KSM is the partition coefficient of the solute between the stationary phase and the micelle [M] may be either the concentration of surfactant or the concentration of micelle Foley used the above equation to determine the solute-micelle association constants and free solute retention factors for a variety of solutes with different surfactants and stationary phases. From this data, it is possible to predict the type and optimum surfactant concentrations needed for a given solute or solutes. Foley has not been the only researcher interested in determining the solute-micelle association constants. A review article by Marina and Garcia with 53 references discusses the usefulness of obtaining solute-micelle association constants. The association constants for two solutes can be used to help understand the retention mechanism. The separation factor of two solutes, a, can be expressed as KSM1/KSM2. If the experimental a coincides with the ratio of the two solute-micelle partition coefficients, it can be assumed that their retention occurs through a direct transfer from the micellar phase to the stationary phase. In addition, calculation of a would allow for prediction of separation selectivity before the analysis is performed, provided the two coefficients are known. The desire to predict retention behavior and selectivity has led to the development of several mathematical models.
=== Covalent catalysis === Covalent catalysis involves the substrate forming a transient covalent bond with residues in the enzyme active site or with a cofactor. This adds an additional covalent intermediate to the reaction, and helps to reduce the energy of later transition states of the reaction. The covalent bond must, at a later stage in the reaction, be broken to regenerate the enzyme. This mechanism is utilised by the catalytic triad of enzymes such as proteases like chymotrypsin and trypsin, where an acyl-enzyme intermediate is formed. An alternative mechanism is schiff base formation using the free amine from a lysine residue, as seen in the enzyme aldolase during glycolysis. Some enzymes utilize non-amino acid cofactors such as pyridoxal phosphate (PLP) or thiamine pyrophosphate (TPP) to form covalent intermediates with reactant molecules. Such covalent intermediates function to reduce the energy of later transition states, similar to how covalent intermediates formed with active site amino acid residues allow stabilization, but the capabilities of cofactors allow enzymes to carryout reactions that amino acid side residues alone could not. Enzymes utilizing such cofactors include the PLP-dependent enzyme aspartate transaminase and the TPP-dependent enzyme pyruvate dehydrogenase. Rather than lowering the activation energy for a reaction pathway, covalent catalysis provides an alternative pathway for the reaction (via to the covalent intermediate) and so is distinct from true catalysis.
3 BrO− ⇌ 2 Br− + BrO3− (K = 1015) Bromous acids and bromites are very unstable, although the strontium and barium bromites are known. More important are the bromates, which are prepared on a small scale by oxidation of bromide by aqueous hypochlorite, and are strong oxidising agents. Unlike chlorates, which very slowly disproportionate to chloride and perchlorate, the bromate anion is stable to disproportionation in both acidic and aqueous solutions. Bromic acid is a strong acid. Bromides and bromates may comproportionate to bromine as follows:
The relative stability of metal ion-protein binding, which affects the conformational stability of metal cofactor-containing proteins in (denaturing) solution, is reflected by the Irving–Williams series.
==== Oral rehydration therapy ==== If prevention has failed and dehydration develops, the preferred treatment is rehydration through oral rehydration therapy (ORT). In severely undernourished children with diarrhea, rehydration should be done slowly, according to the World Health Organization. Oral rehydration solutions consist of clean water mixed with small amounts of sugars and salts. These solutions help restore normal electrolyte levels, provide a source of carbohydrates, and help with fluid replacement. Reduced-osmolarity ORS is the current standard of care for oral rehydration therapy, with reasonably wide availability. Introduced in 2003 by WHO and UNICEF, reduced-osmolarity solutions contain lower concentrations of sodium and glucose than original ORS preparations. Reduced-osmolarity ORS has the added benefit of reducing stool volume and vomiting while simultaneously preventing dehydration. Packets of reduced-osmolarity ORS include glucose, table salt, potassium chloride, and trisodium citrate. For general use, each packet should be mixed with a liter of water. However, for malnourished children, experts recommend adding a packet of ORS to two liters of water, along with an extra 50 grams of sucrose and some stock potassium solution. People who have no access to commercially available ORS can make a homemade version using water, sugar, and table salt.
Sources: en.wikipedia.org
In June 2014, Medtronic announced it would execute a tax inversion to Ireland by acquiring Irish-based Covidien (a previous U.S. tax inversion to Ireland in 2007), for $42.9 billion in cash and stock. The tax inversion enabled Medtronic to move its legal headquarters to Ireland, while maintaining its operational and executive headquarters in the U.S., thus enabling it to reduce taxation on over $14 billion held overseas, and take advantage of Ireland's low corporation tax regime. Medtronic's tax inversion is the largest tax inversion in history, and given the changes in the U.S. tax-code in 2016 to block the Pfizer-Allergan Irish tax inversion, is likely to remain the largest. Medtronic CEO Omar Ishrak defended the tax inversion in a 2015 interview to the Financial Times saying, "We just followed the rules and the deal was done based on strategic merits". Ireland is less than 0.1% of Medtronic (or Covidien) sales, and the majority of Medtronic's sales, and an even greater percentage of Medtronic profits (due to the higher margins on U.S. medical devices), are from the U.S. healthcare system. In 2016, the Star Tribune reported that Medtronic was still winning U.S. Federal contracts and attending U.S. trade-missions as a U.S. company. In terms of scale, on 23 November 2018, Ireland's largest stockbrokers, Davy Stockbrokers reported that the total capitalization of the Irish stock market was €104 billion (this does not include Medtronic, which Davy do not consider an Irish company).
=== Associated conditions === Joint hypermobility may be associated with other conditions. These include ADHD, autism, dyspraxia, fibromyalgia, hereditary connective tissue disorders, mitral valve prolapse, and anxiety disorders such as panic disorder. Joint hypermobility does not cause these other conditions. Most people with joint hypermobility do not have them. In people who do, the underlying cause can be a general syndrome that affects the whole body and brain (such as Autism or Fetal Alcohol Spectrum Disorders), or a genetic condition or disease that affects certain tissues (such as Ehlers-Danlos syndrome or lupus). Hypermobility may be a risk factor for temporomandibular joint dysfunction.
Despite this, the use of urine myoglobin measurement is not supported by evidence as it lacks specificity and the research studying its utility is of poor quality. Elevated concentrations of the enzyme lactate dehydrogenase (LDH) may be detected. Other markers of muscle damage, such as aldolase, troponin, carbonic anhydrase type 3 and fatty acid-binding protein (FABP), are mainly used in chronic muscle diseases. The transaminases, enzymes abundant in both liver and muscle tissue, are also usually increased; this can lead to the condition being confused with acute liver injury, at least in the early stages. The incidence of actual acute liver injury is 25% in people with non-traumatic rhabdomyolysis; the mechanism for this is uncertain. High potassium levels tend to be a feature of severe rhabdomyolysis. Electrocardiography (ECG) may show whether the elevated potassium levels are affecting the conduction system of the heart, as suggested by the presence of T wave changes or broadening of the QRS complex. Low calcium levels may be present in the initial stage due to binding of free calcium to damaged muscle cells. As detectable levels of myoglobinemia and myoglobinuria occur, blood tests and urine tests may show elevated levels of myoglobin. For example, a urine test strip may reveal a positive result for "blood", even though no red blood cells can be identified on microscopy of the urine; this occurs because the reagent on the test strip reacts with myoglobin.
American Zionism was still in its infancy; in 1914 the Zionist Federation had a small budget of about $5,000 and only 12,000 members, despite an American Jewish population of three million but the Zionist organizations had recently succeeded, following a show of force within the American Jewish community, in arranging a Jewish congress to debate the Jewish problem as a whole. This impacted British and French government estimates of the balance of power within the American Jewish public. Avi Shlaim, emeritus Professor of International Relations in the University of Oxford, asserts that two main schools of thought have been developed on the question of the primary driving force behind the declaration, one presented in 1961 by Leonard Stein, a lawyer and former political secretary to the World Zionist Organization, and the other in 1970 by Mayir Vereté, then Professor of Israeli History at the Hebrew University of Jerusalem. Shlaim states that Stein does not reach any clear cut conclusions, but that implicit in his narrative is that the declaration resulted primarily from the activity and skill of the Zionists, whereas according to Vereté, it was the work of hard-headed pragmatists motivated by British imperial interests in the Middle East. Much of modern scholarship on the decision to issue the declaration focuses on the Zionist movement and rivalries within it, with a key debate being whether the role of Weizmann was decisive or whether the British were likely to have issued a similar declaration in any event.
Sources: en.wikipedia.org
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.
There is no single harmonised standard governing these products, and manufacturing conditions differ. Impurities may include truncated sequences, oxidation products, residual solvents, and counter-ions. Independent testing is often the only way to characterise a given lot.
Reported studies have looked at pigmentation, photoprotection, and metabolic or appetite-related endpoints in small experimental settings. Much of the evidence base is early-stage and limited in size. Questions about long-term effects and clinical relevance remain open.
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.